Innovation in bone healing and tissue repair

SEM of standard calcium phosphate   SEM of MagnetOs

Scanning electron micrograph of the surface of standard calcium phosphate granules (left) compared with the surface of MagnetOs granules (right)

MagnetOs granules received CE Mark in mid-2016, obtaining a label as bone void filler in orthopedic, spine and dental indications. In Feburary 2017, 510k approval was achieved to market the product in the US.  The US approval is as a bone graft extender in posterolateral spinal fusion.  A putty formulation is in late-stage development and regulatory submissions are planned for the second half of 2017. 

 

Kuros Biosciences AG
Wagistrasse 25, 8952 Schlieren, Switzerland
Tel: +41 44 733 47 47   Fax: +41 44 733 47 40   Email: info@kuros.ch

About Kuros

  1. Overview
  2. Executive Committee
  3. Board

Products

  1. Pipeline
  2. Orthobiologics
    Fracture repair
    KUR-111
    KUR-113
    MagnetOs
    Spinal fusion
    KUR-113
    MagnetOs
    Solitary Bone Cysts
    KUR-112
  3. Sealants
    Neuroseal (KUR-023)

Technologies

  1. Overview
  2. Surface Science Technology
  3. Synthetic Cross-Linking Technology
  4. Fibrin-Based
  5. Immune Modulation
  6. Publications

Partnerships

  1. Collaborations
  2. Business development

Investors

  1. Share price
  2. Regulatory filings
  3. Reports & presentations
  4. Calendar
  5. Corporate governance
  6. Stay informed

News

  1. Press releases
  2. Conferences & Events

Contact

  1. Location
MagnetOs

SEM of standard calcium phosphate   SEM of MagnetOs

Scanning electron micrograph of the surface of standard calcium phosphate granules (left) compared with the surface of MagnetOs granules (right)

 

MagnetOs granules received CE Mark in mid-2016, obtaining a label as bone void filler in orthopedic, spine and dental indications. In Feburary 2017, 510k approval was achieved to market the product in the US.  The US approval is as a bone graft extender in posterolateral spinal fusion.  A putty formulation is in late-stage development and regulatory submissions are planned for the second half of 2017.